Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib + Spartalizumab in R/M HNSCC
NCT04213404Phase 1Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Mar 2020
- Primary completion
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ribociclib and spartalizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by National Taiwan University Hospital. Primary endpoints: Adverse events at 28 days and Objective Response Rate at 8 weeks. Status: unknown.
02
Drugs
ribociclibspartalizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04213404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04213404.